A rapid assay of endotoxin in whole blood using autologous neutrophil dependent chemiluminescence.

A rapid (30 min) whole blood assay for the detection of lipopolysaccharide (LPS) is described. This chemiluminescent (CL) assay utilizes the CR1 and CR3 receptor-induced oxidant production of polymorphonuclear leucocytes as a detection platform. The differential priming of neutrophils in whole blood by LPS-antibody complexes allows the specificity of the assay to be achieved. Oxidant released in response to complement opsonized zymosan results in luminol oxidation and subsequent light emission. This is dependent on heat labile putative complement proteins in the plasma. The assay consists of a control which measures baseline whole blood neutrophil oxidant production. The test assay contains murine monoclonal IgM antibody against the Lipid A epitope of LPS and measures the enhanced chemiluminescent response of the neutrophils in the presence of LPS-antibody complexes. Maximal sensitivity of the CL assay is dependent upon optimal antigen-antibody equivalence and duration of pre-incubation with the whole blood sample. The quantification of LPS is possible by inclusion of a positive control containing a maximally reactive LPS dose (800 pg/ml Escherichia coli 055:B5 LPS at an antibody concentration of 0.8 microg/assay). The CL assay is insensitive to variations in patient neutrophil concentration over a minimum range of 0.5 to 20 x 10(9) cells/l. The CL assay is widely reactive with the LPS of many strains of gram negative bacteria but not with the cell wall products of gram positive bacteria or Candida and Aspergillus. In comparison to acid extraction chromogenic LAL, the CL assay demonstrates superior recovery precision and accuracy in in vitro studies. This was reproducible over a wide range of LPS concentrations (0.017-1.6 EU/ml or 20-2000 pg/ml). This assay may be a clinically useful tool for the diagnosis of infection or endotoxin in patients.

[1]  J. Tellado,et al.  Modulation of the inflammatory response in severe sepsis , 1995 .

[2]  H. Tamura,et al.  Endotoxin-inactivating activity in normal and pathological human blood samples , 1986, Infection and immunity.

[3]  M. Hazinski,et al.  Epidemiology, pathophysiology and clinical presentation of gram-negative sepsis. , 1993, American Journal of Critical Care.

[4]  Douglas G. Altman,et al.  Measurement in Medicine: The Analysis of Method Comparison Studies , 1983 .

[5]  R. Ulevitch,et al.  CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. , 1990, Science.

[6]  M. Glauser,et al.  Immunotherapy of endotoxemia and septicemia. , 1993, Immunobiology.

[7]  R. Ulevitch,et al.  Mechanisms of Cellular Activation by Endotoxin1 , 1995 .

[8]  J. Pugin.  Recognition of Bacteria and Bacterial Products by Host Immune Cells in Sepsis , 1996 .

[9]  C. McCall,et al.  Tolerance to endotoxin-induced expression of the interleukin-1 beta gene in blood neutrophils of humans with the sepsis syndrome. , 1993, The Journal of clinical investigation.

[10]  S. Deventer,et al.  Intestinal endotoxemia: Clinical significance , 1988 .

[11]  K. Van Dyke,et al.  In vitro evaluation of opsonic and cellular granulocyte function by luminol-dependent chemiluminescence: utility in patients with severe neutropenia and cellular deficiency states , 1978, Infection and immunity.

[12]  H. Brade,et al.  Characterization of the epitope specificity of murine monoclonal antibodies directed against lipid A , 1992, Infection and immunity.

[13]  P. Conlon,et al.  Reactivity of monoclonal antibody E5 with endotoxin. I. Binding to lipid A and rough lipopolysaccharides. , 1992, Circulatory shock.

[14]  J. Hurley,et al.  Concordance of endotoxemia with gram-negative bacteremia in patients with gram-negative sepsis: a meta-analysis , 1994, Journal of clinical microbiology.

[15]  B. Beutler,et al.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. , 1985, Science.

[16]  G. Grau,et al.  Association between protective efficacy of anti-lipopolysaccharide (LPS) antibodies and suppression of LPS-induced tumor necrosis factor alpha and interleukin 6. Comparison of O side chain-specific antibodies with core LPS antibodies , 1990, The Journal of experimental medicine.

[17]  K. Kato,et al.  Participation of lipopolysaccharide-binding protein in lipopolysaccharide-dependent macrophage activation. , 1992, American journal of respiratory cell and molecular biology.

[18]  J. Cavaillon,et al.  Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide , 1993, The Journal of experimental medicine.

[19]  P. Lachmann,et al.  A systematic study of neutrophil degranulation and respiratory burst in vitro by defined immune complexes , 1995, Clinical and experimental immunology.

[20]  T. Kirikae,et al.  Bacterial endotoxin: molecular relationships of structure to activity and function , 1994, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  N. MacIntyre,et al.  A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. , 1995, Critical care medicine.

[22]  R. Bone,et al.  Plasma Cytokine and Endotoxin Levels Correlate with Survival in Patients with the Sepsis Syndrome , 1993, Annals of Internal Medicine.

[23]  D. Bass,et al.  Mechanism of the luminol-dependent chemiluminescence of human neutrophils. , 1982, Journal of immunology.

[24]  H. Tamura,et al.  A new sensitive method for determining endotoxin in whole blood. , 1991, Clinica chimica acta; international journal of clinical chemistry.

[25]  C. Nathan,et al.  Gram‐negative endotoxin: an extraordinary lipid with profound effects on eukaryotic signal transduction 1 , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[26]  G. Schmid-Schönbein,et al.  Circulating neutrophil kinetics during tolerance in hemorrhagic shock using bacterial lipopolysaccharide. , 1994, The American journal of physiology.

[27]  H. Tamura,et al.  Removal of Limulus test-interfering factors in blood samples with perchloric acid and the improvement of the specificity of the Limulus test by fractionating amebocyte lysate. , 1987, Progress in clinical and biological research.

[28]  D. Altman,et al.  STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT , 1986, The Lancet.

[29]  R. Ulevitch,et al.  Participation of tumor necrosis factor in the mediation of gram negative bacterial lipopolysaccharide-induced injury in rabbits. , 1988, The Journal of clinical investigation.

[30]  R. Allen.  Phagocytic leukocyte oxygenation activities and chemiluminescence: a kinetic approach to analysis. , 1986, Methods in enzymology.

[31]  R. Roth,et al.  Optimization of detection of bacterial endotoxin in plasma with the Limulus test. , 1990, The Journal of laboratory and clinical medicine.

[32]  C. Natanson,et al.  Endotoxin in Septic Shock , 1993, Anesthesia and analgesia.

[33]  R. Danner,et al.  Anti-endotoxin monoclonal antibodies. , 1992, The New England journal of medicine.

[34]  J. Parrillo.  Pathogenetic mechanisms of septic shock. , 1993, The New England journal of medicine.

[35]  P. Conlon,et al.  Reactivity of monoclonal antibody E5 with endotoxin. II. Binding to short- and long-chain smooth lipopolysaccharides. , 1992, Circulatory shock.

[36]  R. Allen,et al.  Analysis of circulating phagocyte activity measured by whole blood luminescence: correlations with clinical status. , 1994, The Journal of infectious diseases.

[37]  R. Allen,et al.  Evidence for the generation of an electronic excitation state(s) in human polymorphonuclear leukocytes and its participation in bactericidal activity. , 1972, Biochemical and biophysical research communications.

[38]  J. Levin,et al.  Clottable Protein in Limulus: Its Localization and Kinetics of Its Coagulation by Endotoxin , 1968, Thrombosis and Haemostasis.

[39]  Craig R. Smith,et al.  Treatment of Septic Shock with Human Monoclonal Antibody HA-1A , 1994, Annals of Internal Medicine.